Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CYTOGEN PRESIDENT/CEO IS EX-SMITHKLINE PRESIDENT EBRIGHT

Executive Summary

CYTOGEN PRESIDENT/CEO IS EX-SMITHKLINE PRESIDENT EBRIGHT, who will officially assume his new duties at the New Jersey biotech firm on April 1. George Ebright, 50, will be on the job at the biotech firm a little more than a month following his resignation from SmithKline ("The Pink Sheet" Jan. 30, T&G-2). Ebright brings experience in the diagnositics industry to his new job. A veteran of 26 years with SmithKline, he was executive vice president of the company's diagnostic and analytical products businesses from 1984 to 1986. During that time, Ebright was in charge of revamping Beckman Instruments as well as expanding the clinical labs business. Ebright is also a member of the Halth Industry Manufacturers Association. Ebright takes over the duties which had been held on an interim basis by Cytogen founder and Chairman Robert Johnston. Johnston had been acting president since July 1988, when former president and CEO Ronald Brenner resigned. Commenting on his appointment in a Feb. 21 press release, Ebright stated: "I am impressed by the breadth of the company's technology and the progress the Cytogen team has made. From this, I am convinced, a substantial health care business will be built." Cytogen's OncoScint cancer imaging agent is in Phase III studies and its therapeutic radioisotope product, OncoRad, is entering Phase I testing. The company develops delivery systems for diagnostic and therapeutic agents by linking them to monoclonal antibodies. Via an agreement with Kodak, Cytogen has six cancer imaging compounds in clinical development ("The Pink Sheet" Nov. 28, T&G-7). Cytogen also has a development agreement with Lederle for methotrexate in targeted delivery formulations. Ebright joins a growing number of SmithKline alumni in senior positions with research/start up firms: Cambridge NeuroSciences, for example, is headed by Alan Dalby; and Vestar is headed by Roger Crossley.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel